Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics' stock price has been influenced by positive interim Phase 1 data for ORKA-002 and EVERLAST-B Trial Initiation in January 2026. UBS initiated coverage of ORKA with a buy recommendation, and analysts increased the price target for the stock in January 2026. Oruka Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. The company announced a new board member and a board transition in December 2025. Oruka Therapeutics reported its third-quarter 2025 financial results, highlighting over $500 million in cash and equivalents in November 2025. The company reported its second-quarter 2025 financial results, showing a strong cash position of $351.5 million and increased R&D expenses in August 2025. Between January 30, 2025, and January 29, 2026, the share price increased by 178.02%.

As a clinical-stage biopharmaceutical company, Oruka Therapeutics, Inc. does not currently have commercialized products, and therefore, traditional demand seasonality for its products and services is not applicable. Investor interest and stock performance are more likely to be influenced by clinical data readouts, regulatory updates, and financial reports rather than seasonal consumer demand.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its pipeline includes ORKA-001, a novel monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23p19), currently in Phase 2a and Phase 2b trials. ORKA-002, a monoclonal antibody designed to target both interleukin-17A and interleukin-17F (IL-17A/F), is in Phase 1 trials. ORKA-003 is a preclinical candidate targeting an undisclosed pathway, and ORKA-021 is a preclinical sequential combination regimen of ORKA-002 and ORKA-001.

Oruka Therapeutics, Inc. is headquartered in Menlo Park, California, United States.

Oruka Therapeutics generally holds a positive brand reputation. The company has a news sentiment score of 1.48, indicating a favorable perception in the news. Analyst consensus ratings are "Moderate Buy" or "Strong Buy," with an average price target suggesting significant upside potential. Oruka Therapeutics' stock performance has outperformed both the US Biotechs industry and the broader US market over the past year.

Oruka Therapeutics, Inc. has a mixed ownership structure, with approximately 17.48% to 25.54% of the company's stock owned by Institutional Investors, 16.65% by Insiders, and 8.06% to 57.81% by Public Companies and Individual Investors. Major institutional owners include Fmr Llc, VR Adviser, LLC, Fairmount Funds Management LLC, Viking Global Investors Lp, Deep Track Capital, LP, Vanguard Group Inc, BlackRock, Inc., Rtw Investments, Lp, Commodore Capital Lp, Braidwell Lp, Venrock Healthcare Capital Partners Iii, L.p., iShares, and Fidelity Select Portfolios. Notable individual owners include Peter Harwin and Andreas Halvorsen.